Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Metformin improves endothelial function in type 1 diabetic subjects: a pilot, placebo-controlled randomized study.

Pitocco D, Zaccardi F, Tarzia P, Milo M, Scavone G, Rizzo P, Pagliaccia F, Nerla R, Di Franco A, Manto A, Rocca B, Lanza GA, Crea F, Ghirlanda G.

Diabetes Obes Metab. 2013 May;15(5):427-31. doi: 10.1111/dom.12041. Epub 2012 Dec 5.

PMID:
23167274
2.

Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.

Wang JS, Lin SD, Lee WJ, Su SL, Lee IT, Tu ST, Tseng YH, Lin SY, Sheu WH.

Clin Ther. 2011 Dec;33(12):1932-42. doi: 10.1016/j.clinthera.2011.10.014. Epub 2011 Nov 10.

PMID:
22078152
3.
4.

Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.

De Jager J, Kooy A, Lehert P, Bets D, Wulffelé MG, Teerlink T, Scheffer PG, Schalkwijk CG, Donker AJ, Stehouwer CD.

J Intern Med. 2005 Jan;257(1):100-9.

5.
6.

Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes.

Martens FM, Visseren FL, de Koning EJ, Rabelink TJ.

J Cardiovasc Pharmacol. 2005 Dec;46(6):773-8.

PMID:
16306801
7.

Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD).

Goldfine AB, Buck JS, Desouza C, Fonseca V, Chen YD, Shoelson SE, Jablonski KA, Creager MA; TINSAL-FMD (Targeting Inflammation Using Salsalate in Type 2 Diabetes–Flow-Mediated Dilation) Ancillary Study Team..

Diabetes Care. 2013 Dec;36(12):4132-9. doi: 10.2337/dc13-0859. Epub 2013 Oct 15.

8.
9.

The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients.

Meyer L, Bohme P, Delbachian I, Lehert P, Cugnardey N, Drouin P, Guerci B.

Diabetes Care. 2002 Dec;25(12):2153-8.

PMID:
12453953
10.

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.

PMID:
16882108
11.

Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus.

Kothny W, Foley J, Kozlovski P, Shao Q, Gallwitz B, Lukashevich V.

Diabetes Obes Metab. 2013 Mar;15(3):252-7. doi: 10.1111/dom.12020. Epub 2012 Nov 1.

PMID:
23039321
12.

The effect of metformin on blood glucose control in overweight patients with Type 1 diabetes.

Khan AS, McLoughney CR, Ahmed AB.

Diabet Med. 2006 Oct;23(10):1079-84.

PMID:
16978371
13.

The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS.

Diabetes Care. 1998 May;21(5):701-5.

PMID:
9589227
14.

Improved endothelial function with metformin in type 2 diabetes mellitus.

Mather KJ, Verma S, Anderson TJ.

J Am Coll Cardiol. 2001 Apr;37(5):1344-50.

16.
17.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
18.

Effects of pioglitazone and metformin on vascular endothelial function in patients with type 2 diabetes treated with sulfonylureas.

Naka KK, Papathanassiou K, Bechlioulis A, Pappas K, Kazakos N, Kanioglou C, Kostoula A, Vezyraki P, Makriyiannis D, Tsatsoulis A, Michalis LK.

Diab Vasc Dis Res. 2012 Jan;9(1):52-8. doi: 10.1177/1479164111424515. Epub 2011 Nov 2.

PMID:
22049096
19.

[Metformin in the treatment of type 1 diabetics--a placebo controlled study].

Lacigová S, Rusavý Z, Jankovec Z, Kyselová P.

Cas Lek Cesk. 2001 May 24;140(10):302-6. Czech.

PMID:
11411059
20.

Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study.

Wilding JP, Ferrannini E, Fonseca VA, Wilpshaar W, Dhanjal P, Houzer A.

Diabetes Obes Metab. 2013 May;15(5):403-9. doi: 10.1111/dom.12038. Epub 2012 Dec 7.

PMID:
23163880

Supplemental Content

Support Center